Verified ComparisonLast updated: 31 March 2026
Fragment 176-191 vs Semaglutide
Fragment 176-191 is a GH fragment studied for direct lipolysis. Semaglutide is a well-approved GLP-1 agonist with metabolic effects including weight loss.
HGH Fragment 176-191
Metabolic
3.8/ 5
B+
Semaglutide
Metabolic
4.3/ 5
A−
Editor's note
Semaglutide has robust clinical data and approval; fragment 176-191 is research-phase.
| Criterion | HGH Fragment 176-191 | Semaglutide |
|---|---|---|
| Mechanism | Direct lipolysis (GH-derived) | GLP-1 receptor agonism |
| Regulatory status (AU) | Research-only | Approved |
| Clinical evidence | Research-phase | Extensive, approved-indication |
| Weight-loss efficacy | Emerging data | Robust clinical trials |
| Safety profile clarity | Limited | Well-characterised |
Frequently asked questions
Semaglutide has extensive clinical approval and safety data; fragment 176-191 is research-phase.
Want to read the full reviews?